Affordable Access

deepdyve-link
Publisher Website

Corticosteroid Treatment in Diabetic Macular Edema.

Authors
  • Nurözler Tabakcı, Burcu1
  • Ünlü, Nurten2
  • 1 Ağrı State Hospital, Ophthalmology Clinic, Ağrı, Turkey. , (Turkey)
  • 2 Ankara Training and Research Hospital, Ophthalmology Clinic, Ankara, Turkey. , (Turkey)
Type
Published Article
Journal
Turkish journal of ophthalmology
Publication Date
Jun 01, 2017
Volume
47
Issue
3
Pages
156–160
Identifiers
DOI: 10.4274/tjo.56338
PMID: 28630791
Source
Medline
Keywords
License
Unknown

Abstract

Diabetic macular edema is the most common cause of visual impairment in patients with diabetes mellitus. The pathogenesis of macular edema is complex and multifactorial. For many years, laser photocoagulation has been considered the standard therapy for the treatment of diabetic macular edema; however, few patients achieve significant improvements in visual acuity. Today the intravitreal administration of anti-inflammatory or anti-angiogenic agents together with the use of laser photocoagulation represents the standard of care for the treatment of this complication. The intravitreal route of administration minimizes the systemic side effects of corticosteroids. Steroid-related ocular side effects are elevated intraocular pressure and cataract, while injection-related complications include endophthalmitis, vitreous hemorrhage, and retinal detachment. In order to reduce the risks and complications, intravitreal implants have been developed recently to provide sustained release of corticosteroids and reduce repeated injections for the management of diabetic macular edema. In this review, the efficacy, safety, and therapeutic potential of intravitreal corticosteroids in diabetic macular edema are discussed with a review of recent literature.

Report this publication

Statistics

Seen <100 times